These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16513694)

  • 1. NEJM stands by its criticism of Vioxx study.
    Tanne JH
    BMJ; 2006 Mar; 332(7540):505. PubMed ID: 16513694
    [No Abstract]   [Full Text] [Related]  

  • 2. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
    Dobson R
    BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
    [No Abstract]   [Full Text] [Related]  

  • 3. NEJM editor gives pretrial evidence in Vioxx case.
    Tanne JH
    BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
    [No Abstract]   [Full Text] [Related]  

  • 4. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 5. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 6. Lapses at the new England journal of medicine.
    Smith R
    J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to 'Lapses at the NEJM'.
    Drazen JM
    J R Soc Med; 2006 Oct; 99(10):485; author reply 485. PubMed ID: 17021294
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rofecoxib increases myocardial infarction risk in seniors].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 12. US judge dismisses 50m dollars damages in Vioxx lawsuit.
    Charatan F
    BMJ; 2006 Sep; 333(7567):516. PubMed ID: 16960199
    [No Abstract]   [Full Text] [Related]  

  • 13. 94% of patients suing Merck over rofecoxib agree to company's offer.
    Charatan F
    BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
    [No Abstract]   [Full Text] [Related]  

  • 14. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 15. Court awards claimant 13.5m dollars in rofecoxib lawsuit.
    Tanne JH
    BMJ; 2006 Apr; 332(7547):927. PubMed ID: 16627492
    [No Abstract]   [Full Text] [Related]  

  • 16. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 17. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 18. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 19. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 20. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.